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Abstract
Breast cancer is a heterogeneous disease. Several genetic, environmental and lifestyle factors are involved in the 
aetiology of this disease. Genetic risk factors include alterations (mutations) in genes conferring risks to develop 
breast cancer. Depending on the associated lifetime risks of this malignancy, these genes are categorised into high-, 
moderate- and low-risk genes. Women carrying mutations in these genes are at an increased risk to develop breast 
cancer, ovarian cancer and several other malignancies. Breast carcinoma is the most reported malignancy in Pakistani 
females. Pakistan is a developing country with most of its population living in rural areas; hence, optimal healthcare 
facilities are inadequate for the early diagnosis and prevention of this disease. Hence, identification of individuals 
carrying mutations is clinically relevant as different strategies are available for the early detection, risk reduction 
and better management of this malignancy. This review summarises the findings of the major studies conducted in 
Pakistan to investigate the contribution of breast cancer predisposing genes. Furthermore, implications of the current 
studies and future research potentials are discussed.
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Introduction
Breast cancer is the most frequent invasive malignancy 
diagnosed among women worldwide. It ranks first 
among both the industrialised and developing world.[1] 
The annual incidence rate of ~1.67 million breast cancers 
was reported in the year 2012.[2] It is also the major cause 
of mortality among women worldwide, responsible 
for 0.5 million deaths in the year 2012.[2] Within Asia, 
0.65 million new breast cancer cases were diagnosed 
and 0.23 million died due to this illness in the year 
2012.[2] Breast cancer is the leading public health 
issue in Pakistani women. It is the commonly reported 
cancer among Pakistani females. 34,038 new breast 
cancer cases and 16,232 deaths are reported each year.[3] 
Pakistan has a high incidence of this disease in Asia. 
Women are generally diagnosed at an early age and with 
an advanced disease.[4] Hence, it is crucial to identify 
risk factors of this malignancy and further introduce the 
breast cancer awareness programs and early detection 
strategies.
Breast cancer is a complex disease. A strong interaction 
of genetic and non-genetic risk factors is linked with 
this disease. A large case–control study from Pakistan 
comprising 463 early-onset or familial breast cancer cases 
and 1012 healthy individuals revealed that majority were 
reported with early age at menarche <13 years (58.8% vs. 
53.1%, P = 0.04), a fewer number of full-term pregnancies 
<3 (76.5% vs. 63.5%, P < 0.0001), a later age at full-term 
pregnancy >20 years (57.2% vs. 48.2%, P = 0.02), shorter 
duration of breastfeeding of <23 months (20.5% vs. 12.3%, 
P < 0.0001), post-menopausal (23.1% vs. cancer. Sporadic 
breast cancer develops in an individual without any family 
history of this disease. Such cancers are unilateral and 
present at later ages 17.6%, P = 0.02) and belonged to 
Pathan or Kashmiri ethnicities (16.7% vs. 11%, P = 0.03) 
compared to the control population.[5]
There are three different types of breast cancer including 
sporadic, familial and hereditary breast cancer. Sporadic 
breast cancer develops in an individual without any family 
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history of this disease. Such cancers are unilateral and 
present at later ages.[6] Most breast cancers are sporadic 
and arise due to acquired genetic changes, environmental 
factors and interactions between these factors. Familial 
breast cancer occurs in an individual who reports at least 
one breast cancer among close relatives. This constitutes 
between 15% and 20% of all breast cancers. This form 
of breast cancer develops due to inherited changes in 
moderate- and low-penetrance genes.[7,8] Plausibly, a 
polygenic mechanism of numerous alleles having an 
additive or multiplicative effect[9] and environmental 
factors contribute to disease development. Hereditary 
breast and/or ovarian cancer (HBOC) occur in an 
individual who reports a personal and/or family history 
of at least one breast and ovarian cancer. There are 
parameters suggestive of the hereditary form of the disease 
[Table 1]. Approximately 5–10% of all breast cancers are 
hereditary and occur due to inherited mutations in major 
breast cancer-associated genes.[10]
The genes linked with breast cancer are divided into 
three different categories based on their lifetime 
risk of developing breast cancer. It includes high-
penetrance genes (breast cancer gene 1 [BRCA1], 
BRCA2, tumour protein p53 [TP53] and phosphatase 
and tensin homolog), moderate-penetrance genes (cell 
cycle checkpoint kinase 2 [CHEK2], PALB2, ATM, 
BRIP1, RAD51C and RAD51D) and low-penetrance 
breast cancer loci (single nucleotide polymorphisms 
[SNPs] in Vitamin D receptor [VDR], mitogen-activated 
protein kinase kinase kinase 1, fibroblast growth factor 
receptor 2, lymphocyte-specific protein 1, TNRC19, H19 
and caspase 8).[7] Mutations in high-penetrance genes 
are linked with a high risk (relative risk >5). Moderate-
penetrance genes confer a moderate risk (relative risk 
1.5–5). Low-penetrance genes are associated with low 
risk (relative risk up to 1.5).[7]
Clinical significance of breast cancer predisposing genes 
and associated mutations relies on its prevalence in a 
specific population. In this review, we summarise the 
findings from major studies conducted in the Pakistani 
population explaining the contribution of breast cancer 
susceptibility genes to Pakistani breast cancer patients. 
We also discuss the implications of current studies and 
potential for future research.
High-penetrance Genes BRCA1 and BRCA2
BRCA1 (OMIM 113705) was mapped on chromosome 
17q21 in the year 1990 by linkage analysis of early-onset 
breast cancer families.[11] This gene comprises 110 kb of 
DNA sequence and comprises 24 exons. It encodes 208 
kilo Dalton (kDa) proteins of 1863 amino acid residues. 
BRCA1 has three domains: A RING-finger domain at the 
5’ end, a classic nuclear localisation sequence in the centre 
and a BRCA1 carboxyl-terminal domain at the 3’ end of 
the protein.[12,13]
BRCA2 (OMIM 600185) was mapped on the long arm of 
chromosome 13 (q12–13) in the year 1995.[14] This gene 
includes 70 kb of genomic DNA and comprises 27 exons. 
It encodes a 384 kDa protein of 3418 amino acid residues. 
BRCA2 contains eight copies of 30–80 amino acid repeats 
(BCR repeats) in the centre of the protein.[15]
Table 1: Parameters suggestive of hereditary breast and/or ovarian cancer
Female breast cancer at a young age
Bilateral breast cancer
More than 2 first‑degree relatives affected with breast cancer <50 years of age
The same individual affected with breast and ovarian cancer
Several individuals affected with breast cancer at a young age and ovarian cancer at any age
Male breast cancer
Presence of other BRCA1/2‑associated cancers (e.g., prostate, pancreatic, gallbladder, bile duct and melanoma)
Autosomal‑dominant pattern of inheritance
Few ethnic groups (e.g., Ashkenazi Jewish, Polish and Icelanders) in association with a personal and/or familial history of 
breast and/or ovarian cancer
BRCA1: Breast cancer gene 1, BRCA2: Breast cancer gene 2
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Both BRCA1 and BRCA2 (BRCA1/2) are tumour 
suppressor genes.[16,17] Both genes are involved in the 
maintenance of genomic stability, repair of damaged 
DNA and control of cell cycle checkpoints during the 
process of cell division.[18] BRCA1/2 mutations cause 
early-onset breast cancer, familial breast cancer and 
HBOC. Women harbouring mutations in BRCA1/2 have 
>50% risk of developing breast cancer and 39–44% or 
11–18% risk of developing ovarian cancer by the age of 
70, respectively.[19-21] Among male BRCA1/2 mutation 
carriers, there are 1.2% and 6.8% risk of developing breast 
cancer by the age of 70, respectively.[22]
The frequencies and the spectrum of BRCA1/2 mutations 
vary among different ethnic populations and with 
geographic distributions. Most Asian studies showed that 
the BRCA2 mutations are more common than the BRCA1 
mutations.[23] Conversely, BRCA1 mutations are more 
prevalent in Pakistan.[24-28]
Only one comprehensive study has been conducted 
in Pakistan to assess the contribution of BRCA1/2 
small-range mutations in young and familial breast cancer 
patients.[24] 30 disease-causative mutations in BRCA1 
(n = 23) or BRCA2 (n = 7) were detected in 176 families 
(17.0%). BRCA1/2 mutations were reported with the 
frequency of 23.8% (10/42) for families with at least two 
breast cancer cases and 11.9% (10/84) for young breast 
cancer cases diagnosed ≤30 years. The highest mutation 
frequency of 50.0% (7/14) was reported in HBOC 
families. Four BRCA1 mutations in exon 2, exon 15 and 
exon 24 were identified in multiple unrelated families, 
accounting for 52% (12/23) of all BRCA1 mutations. 
Haplotype analysis showed identical allelic patterns for 
three mutations suggesting founder effects.[24] This study 
highlighted the substantial contribution of BRCA1/2 
mutations in Pakistan.
Two other studies have also assessed the frequency of 
BRCA1/2 small-range mutations in unselected breast 
cancer cases from Pakistan. In the first study by Liede 
et al., 341 cases were analysed for BRCA1 (exon 2, exons 
11–12, exon 15 and exon 20) and BRCA2 (exons 10–11 
and exon 22) and reported that 6.7% (23/341) of patients 
harboured the deleterious mutations in both genes.[25] 
However, screening of unselected patients and limited 
analysis of coding regions of BRCA1/2 genes may have 
compromised the overall strength of this study. In another 
small study, BRCA1/2 mutation screening was performed 
among 77 cases from the Southwestern region of Pakistan 
(Balochistan province) and four mutations were detected 
(5.2%, 4/77).[26]
Large deletions or duplications in BRCA1/2 (large genomic 
rearrangements [LGRs]) have recently been identified 
in breast cancer patients who did not carry small-range 
mutations in these genes. Since small-range mutations in 
BRCA1/2 contributed to only 17% of those breast cancer 
patients diagnosed at a young age or reported a family 
history of breast/ovarian cancer in Pakistan, it became 
necessary to screen these families for BRCA1/2 LGRs. 
A cohort of 120 Pakistani breast cancer patients diagnosed 
≤30 or with the family history of breast/ovarian cancer 
were screened for BRCA1/2 LGRs.[27] Three different 
BRCA1 LGRs were identified in four families (3.3%, 
4/120). Screening of another group of 445 patients for three 
LGRs using deletion-specific polymerase chain reaction-
based assay detected ten more deletions with the frequency 
of 2.2% (10/445). Overall, two BRCA1 LGRs (deletion of 
exons 1–2 and deletion of exons 21–24) were recurrent, 
accounting for 92.8% (13/14) of all identified LGRs. 
BRCA2 LGRs were absent in Pakistani population.[27]
The pathological features of BRCA1/2-associated tumours 
differ from those of non-carriers. This was determined in 
a study considering Pakistani triple-negative breast cancer 
(TNBC) patients.[28] TNBC patients lack the expression 
of progesterone receptor, oestrogen receptor and human 
epidermal growth factor receptor 2. This study included 
523 breast cancer patients, of which 192 were TNBC and 
331 were non-TNBC. BRCA1 mutations were significantly 
associated with TNBC phenotype (37%) as compared to 
non-TNBC (10%).[28] Previously, a Pakistani woman with 
metaplastic breast carcinoma was reported to harbour 
BRCA1 185delAG mutation and further showed TNBC 
features.[29]
It has been reported that BRCA1/2 mutation carrier status 
affects the ratio of female-to-male births, and the mutant 
allele is non-randomly transmitted to female offspring.[30] 
However, sex ratio of offspring of BRCA1/2 carriers 
was not different from the non-carriers in the Pakistani 
population.[31] Males identified with BRCA1/2 mutations 
have an increased risk of multiple cancers.[22] Similarly, 
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we noted a male renal cancer patient from Pakistan, 
carrying BRCA1 2080insA deleterious germline mutation 
with familial aggregation of 25 cancers including breast 
carcinoma.[32]
In humans, almost all individuals harbouring BRCA1/2 
mutation were reported heterozygous. Evidence 
from animal model studies showed that homozygous 
BRCA1/2 mutations are embryonic lethal.[33] Hence, 
human foetuses with homozygous BRCA1/2 mutations 
may be more predisposed to spontaneous abortions. 
Therefore, it is possible that BRCA1/2 mutation carriers 
with a history of parental consanguinity may have more 
rates of miscarriages. To test this hypothesis, Rashid 
et al. investigated the association of miscarriages 
and BRCA1/2 carrier status in Pakistani patients who 
were the progeny of consanguineous parents.[34] The 
study comprised of 128 individuals who had at least 
one pregnancy, including 29 BRCA1/2 carriers and 
99 non-carriers. In agreement with previous reports, 
no association between miscarriage and parental 
consanguinity was observed.[34]
To optimise cancer risk management, it is crucial 
to identify BRCA1/2 mutation carriers. After the 
comprehensive assessment of personal and family 
history, genetic testing is offered to high-risk patients. 
First-degree relatives of the patient harbouring the 
mutation are invited for predictive testing. However, 
interpretation of results becomes challenging among 
families with consanguineous marriages. This aspect is 
recently highlighted in a Pakistani HBOC family with four 
consanguineous marriages. In this family, BRCA1 c.1961 
dupA mutation was detected in the index breast cancer 
patient. As per conventional guidelines, her relatives at 
risk of developing breast/ovarian cancer were offered 
for the family-specific mutation testing. One of the index 
patient’s sisters with ovarian cancer did not carry the 
family-specific mutation. Testing was also offered to her 
daughters as their parents were first cousins. Mutation was 
detected in one daughter, showing that she harboured this 
mutation from her father who was unaffected i.e., without 
any malignancy.[35] The study highlighted the significance 
of family-specific mutation testing to offspring who were 
the progeny of consanguineous parents from Pakistani and 
other populations.[35]
TP53
TP53 (OMIM 191170) is another high-penetrance breast 
cancer susceptibility gene and localised on chromosome 
17p13.1. It covers 25.8 kb of gDNA and has 11 exons. 
TP53 encodes a 43.7 kDa protein of 393 amino acid 
residues. It has six different structural or functional 
domains.[36] p53 plays a key role in transcription, repair 
of damaged DNA, stability of the genome, control of cell 
cycle and apoptosis.[37] TP53 mutations cause Li-Fraumeni 
syndrome (LS) (OMIM 151623). LS is an autosomal 
dominant disorder,[38] of several malignancies including 
breast cancer at the young age, soft tissue sarcoma, lung 
cancer, leukaemia, brain and adrenocortical tumours.[39] 
Women harbouring TP53 germline mutations are prone 
to high lifetime risk of developing cancers (nearly 100%). 
This is due to high incidence rates of breast cancer in 
women while the risks are lower for men (73%).[40]
A TP53 codon 72 SNP is considered as a potential breast 
cancer risk since the substitution occurs within the 
proline-rich domain of p53 and may affect the protein 
structure. However, the results from various populations 
are inconclusive.[41] The frequency of proline allele in 
TP53 codon 72 is more reported in 150 sporadic Pakistani 
patients.[42] Among young breast cancer patients, the 
frequency of TP53 mutations is <5% for Caucasians,[43-45] 
while limited data are available for Asian populations. In 
2012, Rashid et al. analysed the complete TP53 gene in 
105 Pakistani BRCA1/2-negative early-onset breast cancer 
patients diagnosed <40 years of age and not fulfilling the 
criteria of LS. One frameshift mutation (c.499_500delCA) 
was detected with the frequency of 1% (1/105).[46] These 
findings showed a limited contribution of TP53 mutations 
to young Pakistani breast cancer patients.[46]
Moderate-penetrance Genes
Several moderate-penetrance genes are also reported to 
contribute to breast cancer risk. Of these genes, few genes 
have been investigated in the Pakistani population.[47,48]
CHEK2
CHEK2 (OMIM 604373) is mapped on chromosomal 
position 22q12.1. It covers 54.7 kb of genomic DNA and 
has 15 exons. It encodes a 60.9 kDa protein of 543 amino 
acids residues. CHEK2 is a G2 checkpoint serine/threonine 
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kinase. In the event of breakage in DNA double strand, 
CHEK2 acts as a tumour suppressor protein.[49] CHEK2 
has three functional domains: A SQ/TQ cluster domain 
at N-terminus, forkhead-associated domain in the centre 
and a serine/threonine kinase domain at C-terminus.[50]
CHEK2 mutations confer a moderate risk for breast 
and multiple other cancers.[51] Among familial cases, 
different mutations in this gene have been detected with 
varied frequencies and specific to geographical location 
and ethnicity.[52] Women harbouring pathogenic CHEK2 
mutations and with a family history of breast cancer face a 
lifetime risk of breast cancer development of over 25%.[53] 
Most studies were restricted to examine the prevalence of 
common c.1100delC mutation[54,55] since it had been linked 
with the risk of breast cancer among Northern/Western 
European populations.[56,57] This mutation is absent in 
Asian populations,[55,58] including Pakistan[47] and the 
neighbouring regions of India[59] and Iran.[60]
In 2013, Rashid et al. conducted the first comprehensive 
study from Pakistan and screened CHEK2 gene in 145 
young and familial breast/ovarian cancer patients who 
were tested negative for BRCA1/2 mutations. Two 
missense mutations (p.P92R and p.R406C) were identified 
with a frequency of 1.4% (2/145).[47] These mutations were 
absent in 229 early-onset/familial patients not harbouring 
BRCA1/2 mutations. Other two missense mutations 
(p.H371Y and p.D438Y) were reported in another small 
study including 40 unselected breast cancer patients from 
Balochistan.[61] No protein truncating CHEK2 mutations 
were detected in both studies. These findings suggested 
that the CHEK2 mutations may not confer to breast/
ovarian cancer susceptibility in Pakistan.
RAD51C
RAD51C (OMIM 602774) is another moderate-penetrance 
breast cancer susceptibility gene at 17q22. This gene 
covers 43 kb of genomic DNA and has 9 exons. It encodes 
a 42.2 kDa protein of 376 amino acids residues. It is 
crucial in maintaining the stability of the genome through 
homologous recombination and DNA damage repair.
Homozygous RAD51C mutations were reported in one 
Pakistani consanguineous family with characteristics 
of Fanconi anaemia (FA).[62] Later on, heterozygous 
RAD51C mutations were observed in HBOC families.[63] 
Overall, pathogenic mutations in RAD51C were found 
in patients with a family history of HBOC, suggesting its 
association with ovarian cancer.[64] A variable RAD51C 
mutation frequency ranging from 0.6 to 2.9% is reported in 
HBOC families from Caucasian population.[65,66] RAD51C 
mutations were not found in HBOC families from China.[67] 
A large RAD51C deletion (exons 6–9) was reported in 1% 
(1/100) of Japanese HBOC families.[68] So far, only one 
such study is conducted in Pakistan. Analysis of RAD51C 
in 348 Pakistani breast/ovarian cancer patients, who were 
negative for BRCA1/2 mutations, showed three novel 
pathogenic mutations with a frequency of 0.9% (3/348).[48] 
The RAD51C mutations were more frequent in young 
ovarian cancer patients (4.5%, 1/22) than the mutations 
in familial breast cancer patients (0.8%, 1/119). Overall, 
the findings suggested that RAD51C does not contribute 
to breast and ovarian cancer in Pakistani women.[48]
FA complementation group M (FANCM)
Homozygous mutations in four breast cancer predisposing 
genes (BRCA2, PALB2, BRIP1 and RAD51C) are 
involved in the FA pathway. Another gene involved in 
this pathway, the FANCM gene, is recently described 
in Finnish breast cancer families, who did not harbour 
BRCA1/2 mutations.[69] FANCM mutation (p.Q1701X) was 
3.5-fold more prevalent among Finnish TNBC patients 
as compared to the control population. This mutation 
was screened among 117 Pakistani TNBC patients, not 
harbouring BRCA1/2 mutations. It was not detected, 
implying negligible or no contribution of this mutation to 
TNBC development in Pakistani population.[70] However, 
screening of FANCM exon 20 detected a missense 
mutation p.R1644Q in two unrelated early-onset TNBC 
patients with a frequency of 2.7% (2/75). It was predicted 
as deleterious by in silico analyses. The absence of this 
mutation among the control group of 188 healthy Pakistani 
women suggested that it may be a disease-causative. 
These findings warranted whole gene screening to better 
understand the contribution of the FANCM mutations to 
Pakistani TNBC women.[70]
Low-penetrance Breast Cancer Loci and SNPs
Breast cancer risk is also linked with several low-
penetrance breast cancer susceptibility loci and SNPs. BsmI 
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(rs1544410), FokI (rs2228570) and Cdx-2 (rs11568820) 
variants in VDR gene are among the frequently studied 
SNPs and are linked with breast cancer risk.[71-74] VDR 
is mapped on chromosome 12 and encodes for 1α, 25 
dihydroxy Vitamin D3 receptor involved in regulation of 
calcium metabolism and maintenance of mammary gland.[75] 
Decreased expression of VDR has been reported in breast 
tumours and is likely because of VDR gene polymorphisms. 
Conflicting results have been reported among Caucasian 
studies assessing the link of the two common SNPs (BsmI 
and FokI) with breast cancer risk.[72,73,76,77] Insufficient data 
are available for Asian populations.[71,78]
To investigate the role of VDR BsmI and FokI SNPs in 
breast cancer development, a large case–control study 
was conducted in Pakistan comprising 463 early-onset 
or familial breast cancer cases (with known BRCA1/2 
mutation status) and 1012 female controls. An increased 
breast cancer risk was associated with the B allele of 
the BsmI. Further analysis showed that this observation 
was limited to breast cancer patients who did not carry 
the BRCA1/2 mutations. Moreover, this association was 
stronger in familial breast and/or ovarian cancer. No such 
associations for FokI were noted.[5] This study showed 
that VDR gene BsmI b allele is linked with an increased 
breast cancer risk in Pakistani women tested negative 
for BRCA1/2. Another VDR Cdx-2 polymorphism was 
also investigated in a small study comprising 264 pre-
menopausal women from Southern Pakistan: 103 breast 
cancer cases and 161 unaffected individuals. No significant 
association of this SNP was noted with breast cancer risk.[79] 
Current Challenges and Future Perspectives
The age-standardised incidence rate (ASR) of breast 
cancer in Pakistan (ASR = 50.3) is lower than in North 
America (ASR = 92.9) and Europe (United Kingdom, 
ASR = 95, and Belgium, ASR = 111.9).[3] However, the 
corresponding mortality rate in Pakistan (ASR = 25.2) 
is higher than in North America (ASR = 14.9) and 
Europe (United Kingdom, ASR = 17.1, and Belgium, 
ASR = 20.3). This may be due to distinct genetic spectrum 
and underlines the emerging concern of poorly defined 
healthcare facilities for the early diagnosis and treatment 
of breast cancer in Pakistan. Well-defined breast cancer 
studies and cancer screening policies may help to avoid 
such health disparities.
Breast cancer-associated syndromes also need to be 
considered to comprehend interlinking genetic factors. As 
an example, a novel pathogenic germline mutation was 
identified in the MSH2 gene of a Pakistani breast cancer 
patient, who did not carry mutations in BRCA1/2, CHEK2 
and RAD51C genes. This patient also reported a family 
history of malignancies within the spectrum of Lynch 
syndrome with a phenotypic overlap of HBOC.[80] The 
optimisation of cancer risk management is challenging as 
overlapping cancer syndromes can add to the complexity 
of both genetic counselling and preventive strategies. 
Therefore, cancer geneticist needs to accompany 
oncologists to assess the appropriate susceptibility 
gene(s). This kind of service is only provided at the 
Shaukat Khanum Memorial Cancer Hospital and Research 
Centre (SKMCH and RC), to the breast/ovarian cancer 
families enrolled in genetic testing studies.
Studies conducted so far have shown a substantial 
contribution of BRCA1/2 germline mutations to breast 
cancer in Pakistani women. Further studies are warranted 
to analyse the prevalence of recurrent mutations in 
unselected breast cancer patients from this population. 
Despite extensive research, a large number of familial 
breast cancer cases are with unknown mutations.[81] 
Technical advances such as next-generation sequencing 
facilities are now available to detect mutations in such 
cases.[82] Using such technology for routine genetic 
testing requires critical consideration, in the context of 
mass screening in an economically challenged country 
like Pakistan.
Conclusion
About one in nine Pakistani women develops breast 
cancer during her lifetime.[83] Since 2001, substantial 
research work is performed at SKMCH and RC to 
explore the prevalence and spectrum of major breast 
cancer susceptibility genes and SNPs in Pakistan. The 
knowledge obtained from these studies has enhanced 
our understanding about the contribution of major genes 
to Pakistani breast cancer. These findings will also be 
applicable to define appropriate strategies for the early 
diagnosis of breast cancer and also for better preventive 
and treatment. Comprehensive mutation analysis of the 
BRCA1/2, TP53, CHEK2, RAD51C, FANCM and VDR 
genes has been performed. All those samples revealing 
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variants from these analyses were confirmed for the 
presence of mutations by DNA sequencing. In conclusion, 
the studies showed that mutations in BRCA1 and BRCA2 
substantially contribute to HBOC in Pakistan. The 
studies provide evidence for other predisposing gene(s) 
contributing to breast and ovarian cancer development. 
However, TP53, CHEK2, RAD51C and FANCM mutations 
are less frequent in Pakistan. Overall, high-penetrance 
breast cancer susceptibility genes (BRCA1, BRCA2 
and TP53) and moderate-penetrance genes (CHEK2, 
RAD51C and FANCM) account for ~25% of breast cancer 
patients who were diagnosed at a young age or having 
a family history of breast/ovarian cancer. Knowledge 
of BRCA1/2 mutation spectrum in a specific population 
has implications in risk-reducing strategies for high-
risk breast cancer patients.[84] Prophylactic bilateral 
mastectomy and/or oophorectomy reduce breast and 
ovarian cancer risk in women with BRCA1/2 mutation.[85] 
Offering extensive predictive genetic testing and genetic 
counselling to consanguineous families are also relevant 
in the Pakistani population.[35] However, the facility of 
pre- and post-test genetic counselling in Pakistan is only 
provided at SKMCH and RC. Genetic testing for breast 
cancer predisposition in Pakistan may allow physicians 
to detect those women susceptible to breast and ovarian 
cancer and allow them to tailor preventive and therapeutic 
modalities based on their genotypes.
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